Results 51 to 60 of about 255,779 (244)
PD-L1 blockade enhances anti-tumor efficacy of NK cells
OncoImmunology, 2018 Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors.
Jeremiah L. Oyer +3 more
doaj +1 more source
Journal of the Egyptian National Cancer Institute, 2018 Cancer immunotherapy targeting programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway has shown promising results in treatment of non-small cell lung cancer (NSCLC) patients.
Dina M. El-Guindy +3 more
doaj +1 more source
Frontiers in Immunology, 2020 Targeting PD-L1 and PD-1 interactions is a relatively new therapeutic strategy used to treat cancer. Inhibitors of PD-1/PD-L1 include peptides, small molecule chemical compounds, and antibodies.
Libin Guo +3 more
doaj +1 more source
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. [PDF]
, 2017 BACKGROUND: The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators to implement novel clinical trials which combine immunotherapy with different treatment modalities. Moreover is also important to investigate
Anniciello, Anna Maria +17 more
core +2 more sources
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity
Molecular Oncology, EarlyView.Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek +2 more
wiley +1 more source
Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL. [PDF]
, 2019 The risk for non-Hodgkin lymphoma (NHL) is markedly increased in persons living with human immunodeficiency virus (HIV) infection, and remains elevated in those on anti-retroviral therapy (cART).
Conti, David V +5 more
core
Hantavirus-driven PD-L1/PD-L2 upregulation: An imperfect viral immune evasion mechanism [PDF]
, 2018 Viruses often subvert antiviral immune responses by taking advantage of inhibitory immune signaling. We investigated if hantaviruses use this strategy.
Abdelaziz, Mohammed O. +3 more
core +2 more sources
Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer
Molecular Oncology, EarlyView.COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann +61 more
wiley +1 more source
Molecular Oncology, EarlyView.We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric +10 more
wiley +1 more source
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Scientific Reports, 2017 In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials.
Hyun Tae Lee +8 more
doaj +1 more source